Introduction
Matricellular proteins were first described by the team of Paul Bornstein 20 years ago, in order to characterize a family of non-structural proteins secreted in the extracellular matrix (ECM). Some of the most well-known members of the family include CCNs, thrombospondins, osteopontin, periostin, secreted protein acidic and rich in cysteine (SPARC), and tenascins. These proteins are dynamically expressed by several cell types into the ECM, but they do not represent primary structural components of the matrix; instead, they mediate the interaction between cells and their surrounding microenvironment modulating cell function [1, 2] .
Presently, matricellular proteins are well described to display certain distinct characteristics. First, their expression is tightly regulated, being highly induced during development or under pathological conditions. Secondly, they are capable of interacting with a large variety of matrix proteins, cell-surface receptors, and cytokines present in the ECM which accounts in large part for the complexity of their functions. Moreover, most of these proteins fail to support cell adhesion, while they induce an intermediate adhesive state characterized by formation of focal adhesions and stress fibers. Lastly, contrary to the initial anticipation, a targeted disruption of the genes of most matricellular proteins in the mouse presents only a subtle or no apparent phenotype [1, 2] .
The key function of matricellular proteins to mediate communication and modulate the signaling between cells and their extracellular environment has introduced them as potentially crucial players in several pathophysiological conditions, such as embryogenesis, angiogenesis, cancer, or chronic wound healing. This review will summarize the recent findings on matricellular proteins in the field of organ fibrosis by taking a closer look at each protein separately in different tissues and models of fibrosis. The advances towards a potential usage of This article is part of the Topical Collection on Activated Myofibroblasts and Fibrosis in Various Organs matricellular proteins as therapeutic targets to treat fibrosis will also be discussed.
Wound Healing and Fibrotic Diseases
Wound repair is a complex fundamental process that takes place in all mammalian tissues after exposure to an injurious stimulus. The normal response to injury comprises of three distinct but overlapping phases: inflammation, new tissue formation, and remodeling. Initially, inflammatory pathways are activated and immune cells are recruited at the site of injury in order to prevent blood loss and infections or remove cell debris. In a second time, new tissue formation occurs characterized by re-epithelialization, angiogenesis, and granulation tissue formation. At this stage, activated fibroblasts differentiate into myofibroblasts which proliferate and produce high amounts of ECM to support the repair of the damaged tissue. At the last phase, all unnecessary cells undergo apoptosis or exit the wound, while excess matrix is remodeled in the final step to restore the original tissue architecture. However, excessive ECM deposition may occur in case of chronic wound healing which leads to fibrosis, tissue degeneration, and dysfunction. The multiple steps linking wound healing to fibrosis are illustrated in Fig. 1 . Fibrosis plays a major role in the pathology of chronic diseases in many organs; for example, in case of myocardial scar formation after infarction, fibrosis in the liver or the lung after viral infections or toxic injuries, or fibrosis in the kidney triggered by chronic occurrence of diabetes or hypertension [3, 4] . Although these pathologies can impair tissue function and lead to death, there is still no available treatment targeting fibrosis. Recent findings indicate that several matricellular proteins contribute to tissue remodeling by promoting or inhibiting fibrosis, and therefore may serve as intriguing novel targets of therapy against fibrotic diseases.
Matricellular Proteins in Fibrotic Diseases
CCNs CCN proteins comprise a family of six cysteine-rich homologous members that have been denominated CCN1-6 according to international nomenclature. The CCN acronym was introduced from the names of the first three members of the family that were identified: cysteine-rich 61 (CYR61/CCN1), connective tissue growth factor (CTGF/CCN2), and nephroblastoma overexpressed (NOV/CCN3). The last three members of the family were discovered as Wnt-inducible signaling pathway proteins (WISP) [4] .
CCN2 is the most extensively studied member of the family which has been shown to function as a pro-fibrotic mediator in nearly every organ or tissue, including the heart, kidney, liver, and lung [4, 5] . CCN2 was shown to exert its functions through direct activation of cells to produce ECM, induction of cell cycle arrest or hypertrophy, and conversion of Fig. 1 Multiple steps from inflammation to fibrosis resident cells to activated myofibroblasts. CCN2 acts downstream the pro-fibrotic cytokine TGFβ, but it has also been shown to activate or co-activate TGFβ through binding to cell-surface receptors like tropomyosin-related kinase A (TrkA) and activation of downstream signaling which prevents the expression of inhibitory Smad7 [6•, 7] . More recent findings verified the pro-fibrotic role of CCN2 in the mdx mouse model of muscular dystrophy, since hemizygous mice or mice treated with an anti-CTGF monoclonal antibody showed improved muscle strength, reduced apoptotic damage, and fibrosis [8] . Another study on the same model found that ACE inhibition reduced muscle damage and ECM accumulation by inhibiting the expression of CCN2 [9] . Interestingly, RNA interference silencing CCN2 in activated primary cardiac fibroblasts was found to block multiple proinflammatory and pro-fibrotic pathways, demonstrating that CCN2 is a central regulator in these processes [10•].
Contrary to the well-established pro-fibrotic role of CCN2, the functions of three other members of the family, CCN1, CCN3, and CCN5, have been rather controversial. These proteins are mainly considered to possess anti-fibrotic functions, however certain studies have also revealed opposite effects. Several recent studies on models of liver fibrogenesis have pinpointed the anti-fibrotic role of CCN1 [11] [12] [13] . In one study, hepatocyte-specific deletion of CCN1 exacerbated fibrosis, while CCN1 overexpression or tail vein delivery of recombinant protein attenuated the fibrotic phenotype. CCN1 was shown to exert this function by triggering ER stress and ROS production in activated hepatic stellate cells (HSCs) to induce cellular senescence and apoptosis. On the other hand, recent findings have shown that CCN1 overexpression through adenovirus-mediated gene transfer in mouse lungs induces acute lung injury evident by increased bronchoalveolar lavage (BAL) neutrophil counts, protein concentrations, weight loss and mortality, while increased CCN1 expression was also observed in biopsies from patients with idiopathic pulmonary fibrosis (IPF) [14] . CCN3 has also been shown to play a role in models of hepatic fibrosis, where it was found increased in activated HSCs. In vitro, treatment of cells with pro-fibrotic cytokines suppressed CCN3 expression, while treatment with CCN3 siRNA enhanced the expression of pro-fibrotic marker proteins [15] . In animal models of diabetic nephropathy (DN), intraperitoneal injections with recombinant CCN3 reduced the renal expression of profibrotic markers and prevented the establishment of glomerular fibrosis and podocyte loss [6•]. On the contrary, CCN3 KO mice were protected in the unilateral ureteral obstruction (UUO) model of renal fibrosis, displaying reduced inflammation and fibrosis, while CCN3 was consistently found increased in biopsies of tubulointertitial nephritis patients [16] . Lastly, CCN5 may be considered as a natural inhibitor of CCN2, since it suppresses the expression of CCN2 in fibroblasts, concomitantly with that of several pro-fibrotic molecules, preventing myofibroblast transformation [5, 17, 18] . Overexpression of CCN5 in mouse models of IPF or myocardial fibrosis decreased fibrosis and preserved organ function.
Thrombospondins
Thrombospondins (TSPs) are highly conserved, multi-domain, calcium-binding glycoproteins of connective tissues. There are five TSP genes in mammals which are divided into two subgroups. TSP1 and TSP2, belonging in subgroup A, represent trimeric proteins with low expression in normal ECM which are transiently induced in tissue injury and remodeling conditions. TSP3, TSP4, and TSP5 are subgroup B TSPs and constitute pentameric highly abundant components of the ECM in cartilage, bone, tendons, and blood vessel walls Most work on the involvement of TSPs in organ fibrosis has been focused on the prototype member of the family, TSP1, in part because of its ability to activate latent TGF-β1 and its angiostatic function. A recent study in Col4a3 KO mice which develop spontaneous renal failure revealed that TSP1 deficiency induced a shift from a fibroproliferative to an inflammatory phenotype with less collagen accumulation and reduced activation of latent TGF-β1 [20] . Separate studies on animal models of renal disease also confirmed the profibrotic role of TSP1. In a high-fat diet mouse model, wildtype obese mice showed increased expression of TSP1 in the kidney and developed albuminurea, renal hypertrophy, and fibrosis, while these effects were abrogated in TSP1 KO mice. The authors treated primary isolated mesangial cells with leptin and showed that leptin-stimulated ECM production was abolished by TSP1 deficiency [21] . Moreover, TSP1 deficiency or treatment with shRNA against TSP1 was protective in mouse UUO, leading to decreased inflammation and fibrosis, increased VEGF expression, and preserved endothelial capillary network [22, 23] . TSP1 was also found to mediate highfat diet-induced skeletal muscle fibrosis or diabetes-induced myocardial fibrosis by either inducing collagen expression or inhibiting collagen degradation through regulation of MMP2 and MMP9 activities, respectively [24, 25] .
Several studies have also demonstrated a role for TSP2 in development of fibrosis with, however, contradictory results. In a mouse cardiomyocyte grafting model, lack of TSP2 led to reduced fibrosis and peri-graft scar thickness, while endothelial cell density and cardiomyocyte graft size were increased [26] . Moreover, TSP2 was the only TSP increased in fibrosclerotic and stenotic aortic valves of patients with calcific aortic valve disease, expressed in valvular myofibroblasts and neovessels [27] . In patients with systemic sclerosis (SSc), TSP2 serum levels were increased and correlated with the severity of the disease. Primary fibroblasts isolated from these patients showed increased expression of TSP2 in their conditioned medium, while TSP2 knock-down inhibited the expression of collagen type I [28] . On the contrary, a study on doxorubicin-induced cardiomyopathy revealed opposite effects; TSP2 KO mice showed depressed cardiac function, increased scar formation, and cardiomyocyte apoptosis attributed to impaired activation of the Akt pathway [29] .
Periostin
Periostin (Postn) is a 90-kDa secreted protein with adhesive function, mostly abundant in periosteum, periodontal ligament, bone, skin, and developing heart. The protein is composed of four fasciclin domains which derive from the insect fasciclin I domain, known to mediate neuronal adhesion. Postn has been shown to directly interact with ECM components like collagen I, tenascin C, and fibronectin in order to promote collagen fibrilogenesis, as well as several surface integrins to mediate cell adhesion and migration. The expression of Postn is dynamically regulated being highly induced during development and tissue remodeling, while it is also highly upregulated by TGF-β1 [30, 31] .
Certain important studies few years ago were the first to indicate the crucial role of Postn during cardiac healing. In mouse acute myocardial infarction (AMI) models, the absence of Postn led to impaired healing and death because of reduced myocardial stiffness and impaired collagen fibrilogenesis. On the other hand, mice surviving infarction or subjected to longterm pressure overload were protected from hypertrophy and fibrosis [31, 32] . Most recent studies have verified the deleterious effect of Postn in chronic cardiac fibrosis models [33] [34] [35] . Kaur et al. showed that Postn is the marker with the highest correlation to an activated cardiac fibroblast phenotype, while targeted ablation of Postn-expressing fibroblasts reduced fibrosis and improved cardiac function after AMI or Ang-II exposure [36] . Interestingly, another study applied a selective blockade of Postn using a targeted neutralizing antibody, thus linking the deleterious function of Postn in the heart to a specific region of the full-length Postn isoform [37•]. These results suggest that Postn may play a differential role in acute vs. chronic injury.
Postn was shown to be highly expressed in the lungs of patients with IPF and asthma downstream of IL-13. In animal and in vitro studies, Postn was shown to mediate pulmonary fibrosis by promoting the production of pro-inflammatory cytokines and inducing secretion of collagen by lung fibroblasts [38] [39] [40] . In recent clinical studies, high serum Postn levels could predict a shortened survival and worsened outcome with increased fibrosis in patients with IPF [41•] . Moreover, clinical trials with type 2 immune response antagonists showed good efficacy in asthmatic patients with high serum Postn levels [42•] .
We were among the first to discover that Postn was highly induced during chronic kidney disease (CKD) being well correlated with progression or reversal of the disease and with classical indexes of renal function [43] . Moreover, we showed that Postn deficiency or antisense delivery against Postn was largely protective in CKD models leading to less inflammation and fibrosis [44] . Induction of Postn was attributed to proinflammatory pathways, while its deleterious function was linked to activation of integrin signaling [45] . In parallel, other studies mainly performed on renal biopsies highlighted the overexpression of Postn in several renal diseases, including focal segmental glomerulosclerosis, mesangial and IgA nephropathy, diabetic nephropathy, lupus nephritis, and polycystic kidney disease, also correlating its expression levels with renal function [46] [47] [48] [49] . On the other hand, the potential role of Postn in acute kidney injury has not been examined yet.
Postn has been also found particularly upregulated in other fibrotic diseases, like various skin pathologies, muscular dystrophy, or liver fibrosis, with KO mice being protected towards progression of the disease in animal models [50] [51] [52] [53] [54] . The function of Postn in dermal fibroblasts or HSCs was associated with activation of the cells towards a proliferative and ECM-producing phenotype. Interestingly, in acute versus chronic skeletal muscle injury models, Postn showed a similar function as in cardiac healing, being transiently expressed to assist in myotube regeneration or persisting with stable overexpression in fibrotic compartments, respectively [55•] . In a recent study on a laser-induced choroidal fibrosis model, local application of a new class siRNA against Postn drastically inhibited fibrosis formation, indicating the potential utility of Postn-targeting drugs for therapeutic applications towards fibrosis [56•] .
Osteopontin
Osteopontin (OPN) is a multifunctional protein abundantly expressed in bone as an organic component, but also expressed by a variety of other tissues and cell types, such as fibroblasts, immune cells, smooth muscle cells, endothelial cells, and several epithelial cell types. OPN is upregulated by pro-inflammatory cytokines such as TNF-α or TGF-β and has been shown to play critical roles in inflammation and tissue repair of several organs. The diversity of OPN functions has been related to its extensive post-translational modifications and interactions with various integrin and CD44 receptors, mediating cell activation, cell attachment, and immune system modulation [57] [58] [59] .
Many recent studies have focused on the implication of OPN in hepatic fibrosis. In several of these studies, OPN deficiency or neutralization protected from progression of fibrosis in various mouse models [57, 58] . Pritchett et al. showed that the transcription factor SOX9 controls the upregulation of OPN in HSCs in rodent and human hepatic fibrosis [59] . In a recent study, OPN was shown to promote the acetylation of nuclear HMGB1 and translocation to the cytoplasm leading to enhanced collagen I expression in HSCs [60] . A clinical study on a large group of HCV patients revealed that serum OPN levels were progressively increased and correlated with the progression of fibrosis, indicating its potential use as a prognostic factor [61] . On the other hand, OPN or OPN-related signaling pathways were shown to participate in liver regeneration after partial heparectomy and have protective role in experimental alcoholic hepatitis [62, 63] .
OPN has been also shown to affect the progression of cardiac, renal, pulmonary, and muscle fibrosis. In a recent clinical study, OPN was found increased in the fibrotic tissue and plasma of patients with calcific aortic valve disease and it was shown to function by directly inhibiting the proliferation of cultured endothelial and valvular interstitial cells of aortic valves [64] . In a chronic cardiac fibrosis model, OPN was necessary for the AP1-mediated induction of pro-fibrotic miR-21 [65] . On the contrary, OPN was found to be protective in AMI models, either by promoting fibroblast migration and collagen expression through its N-terminal domain, or by inducing antioxidative mediators, chemokines, and cardiomyocyte contraction [66, 67] . In animal models of renal fibrosis, OPN was expressed by injured epithelial cells and it was shown to be regulated by transcriptional activation through AP-1 and to enhance the macrophage recruitment and the pro-fibrotic phenotype of pericytes [68] [69] [70] [71] . White et al. showed that the serum levels of OPN could function as biomarker in pulmonary fibrosis by distinguishing IPF patients from alternatively idiopathic ones [72] . Moreover, OPN was recently shown to play a role in the phenotypic polarization of inflammatory cells; in bleomycin-induced pulmonary fibrosis, OPN promoted the disease by inducing the Th17 and inhibiting the Th1 differentiation, while in a muscle degeneration model OPN ablation reduced fibrosis and improved muscle strength by changing macrophage polarization to a pro-regenerative M2c phenotype [73, 74•] .
Tenascins
Tenascins are a family of large oligomeric ECM glycoproteins consisting of four members, tenascin C, X, R, and W, with similar characteristics but differing expression patterns [75, 76] . Among them, tenascin C (TN-C) has been mostly associated with fibrotic and tissue remodeling conditions, since contrary to the other family members it shows limited expression in adult tissues but is de novo induced after injury. TN-C has been shown to interact via its multiple domains with several cell-surface receptors including integrins α9β1, αvβ3, αvβ6, and toll-like receptor 4 (TLR-4), controlling cell adhesion, motility, proliferation, differentiation, and survival.
While several past studies showed the upregulation of TN-C and examined its role in fibrotic diseases of various organs [75] , recent research has been mostly focused on the identification of TN-C as biomarker for disease progression. In cardiac disease, re-expression of the fetal splicing variant B+ TN-C in the heart or serum was correlated with signs of rejection of transplanted subjects or decreased survival and increased risk to undergo transplantation in a group of dilated cardiomyopathy patients [77, 78] . High TN-C serum levels were shown to predict a greater incidence of maladaptive cardiac remodeling and worse prognosis in AMI patients [79] . Moreover, TN-C was suggested as a marker to distinguish inflammatory cardiomyopathy from other types of cardiac disease, which would improve the management of patients [76] . Another recent study showed that TN-C promotes inflammation by inducing macrophage migration and secretion of proinflammatory cytokines through activation of integrin avβ3, subsequent phosphorylation of FAK, and nuclear translocation of NFκB [80] .
High TN-C levels were also detected in serum and biopsy samples from patients with scleroderma and in fibrotic skin of mice [81, 82] . Secreted TN-C was described to act through TLR-4 in a mouse model of scleroderma to stimulate collagen expression and myofibroblast transformation. Similarly, TN-C was shown to affect hepatic fibrosis by stimulating HSCs to increase production of collagen I through signaling via integrin a9β1 [83] . In idiopathic interstitial lung diseases, TN-C was found upregulated both in fibroblasts and alveolar epithelial cells of patients and was shown to mediate TGF-β-induced collagen deposition and Smad signaling [84] [85] [86] . Moreover, fibroblasts lacking TN-C have an increased capacity to digest fibrin which could explain the correlation of TN-C and fibrin deposition in several fibrotic disorders [87] . A recent interesting study proposed a novel role for TN-C as an important component of the fibrogenic niche which facilitates fibroblast proliferation and expansion of fibrosis. The authors showed that TN-C was produced by fibroblasts and localized in fibrogenic foci in two models of kidney fibrosis, while it induced fibroblast proliferation and activation of proliferation-related genes through an integrin/FAK/mitogen-activated protein kinase pathway, both in vivo and in vitro [88•] .
SPARC
SPARC is a collagen-binding protein secreted by various cell types into the ECM. Several studies have reported elevated expression of SPARC in fibrosis of many tissues including the heart, lung, skin, kidney, and liver, showing that absence of SPARC results in significant attenuation of ECM deposition. SPARC has been described to function by binding to procollagen which inhibits its interaction with cell-surface receptors and stimulates collagen processing and incorporation into insoluble fibers [89, 90•] .
In a recent study, SPARC deletion attenuated myocardial stiffness and collagen content in aged mice attributed to decreased expression and activity of ADAMTS1 metalloproteinase [91] . Apart from its high expression by fibroblasts during organ fibrosis, SPARC was also found to be produced by circulating inflammatory cells, mainly macrophages, regulating their extravasation into the fibrotic interstitium of the heart and lung [90•]. Sangaletti et al. proposed a differential function of SPARC in fibroblasts and macrophages in a model of bleomycin-induced lung fibrosis; using SPARC-depleted mice and bone marrow chimeras, they found that SPARC expression by fibroblasts was required to induce collagen deposition, while SPARC depletion from macrophages caused exacerbated inflammation and fibrosis because of their inability to downregulate TNF-a production [92] . In another study, SPARC was required for H 2 O 2 production by lung fibroblasts after TGF-β1 treatment, while SPARC knock-down in fibroblasts attenuated epithelial cell injury in a co-culture system [93] . In liver fibrosis, SPARC is upregulated in activated HSCs and mediates their migration towards TGF-β1 and TGF-β1 secretion [94] . Aseer et al. recently showed a differential expression of SPARC in the liver and pancreas of streptozotocin-induced diabetic rats; SPARC was upregulated in the liver accompanied by TGF-β1 induction and elevated fibrogenesis, while it was downregulated in the pancreas accompanied by chronic inflammation and strong expression of inflammatory genes [95] . Increased SPARC expression in the bone marrow stroma was also shown to contribute to myelofibrosis, while its deficiency induced an enhanced myeloproliferative response [96] . Interestingly, a recent study showed that SPARC siRNA could be encapsulated in nanoparticles leading to a significant target gene knock-down in cultured cells without any cytotoxicity, introducing a novel technology for the targeted inhibition of SPARC to treat fibrosis [97] . 
Matricellular Proteins as Biomarkers or Therapeutic Targets of Fibrosis
Several studies have explored the utility of matricellular proteins as biomarkers both in animal and human biofluids and tissue samples, while their potential as targets of therapy has mostly been examined in animal models of fibrosis to date. In pulmonary fibrosis or asthmatic patients, serum Postn levels could efficiently predict a worsened outcome or resistance to therapy [41•, 42•] . Moreover, plasma levels of OPN could distinguish subgroups of lung disease patients [72] . In terms of therapy, adenoviral CCN5 overexpression or treatment with a blocking antibody against Postn limited collagen deposition in IPF mouse models [18, 40] . In several studies, increased serum TN-C levels in cardiac disease patients were associated with worse prognosis, adverse cardiac remodeling, and increased risk to undergo transplantation [77] [78] [79] . Cardiac overexpression of CCN5 or antibody targeting of Postn preserved cardiac function and decreased myocardial fibrosis [5, 37•]. Interestingly, normalization of matricellular protein expression by aldosterone receptor antagonism further improved cardiac structure and function in addition to standard pharmacological heart failure therapy [98] . In liver disease patients, increased serum OPN levels correlated with the degree of fibrosis, while OPN neutralization in mice protected from liver fibrosis progression [58, 61] . CCN1 delivery via tail vein could also attenuate hepatic fibrosis [13] . In animal models of kidney fibrosis, delivery of recombinant CCN3 or antisense targeting of Postn could ameliorate the progression of the disease [6•, 44, 45] . Elevated serum and tissue levels of TN-C were associated with increased number of lesions and higher skin thickness in scleroderma patients [81, 82] . In a mouse model of choroidal fibrosis, new generation RNA interference against Postn could inhibit fibrosis formation [56•] . Of note, pharmaceutical industries are becoming interested in the development of matricellular protein-based drugs to treat fibrosis, with few molecules currently in preclinical or clinical studies [6•]. The recent utilization of matricellular proteins as markers or targets of therapy in clinical studies and models of fibrosis is summarized in Table 1 .
Conclusions
Since their identification, matricellular proteins have evolved as crucial players in fibrotic diseases which renders them intriguing therapeutic targets. The last years, large amounts of knowledge have been obtained on the differential function of these proteins as mediators or inhibitors of the progression of fibrosis in nearly every body organ, denoting their value as biomarkers or targets in a variety of therapeutic strategies. Notably, although they share common characteristics, several of these proteins were found to serve distinct functions in different disease contexts, suggesting that the use of matricellular proteins for prognostic or therapeutic purposes should be targeted and dependent on the disease background. These studies have contributed to our deeper understanding of the various roles of matricellular proteins and paved the way for the development of convenient detection systems or efficient drugs targeting matricellular proteins for future use in fibrosis patients.
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